Categories: Market Research

CRISPR And Cas Gene Market Size and Forecast 2024-2033|F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., AstraZeneca plc., Danaher Corporation, Quest Diagnostics

The CRISPR And Cas Gene Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The CRISPR And Cas Gene Market:

https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

According to The Business Research Company’s CRISPR And Cas Gene Global Market Report 2024, The crispr and cas gene market size has grown exponentially in recent years. It will grow from $3.28 billion in 2023 to $3.97 billion in 2024 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to increased consumer awareness, shift in consumer values, rise in celebrity endorsements, rise of veganism, increased social media influence.

The crispr and cas gene market size is expected to see exponential growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 20.5%. The growth in the forecast period can be attributed to global expansion of bans, rising conscious consumerism, emergence of new brands, consumer education initiatives, beauty inclusivity. Major trends in the forecast period include technology advancements, product innovations, circular beauty economy, men’s grooming segment, social justice and ethical sourcing.

A growing focus on personalized therapy is expected to propel the growth of the CRISPR and Cas gene markets going forward. Personalized therapy refers to a medical model that uses an individual’s genetic profile to guide decisions made concerning the diagnosis, treatment, and prevention of disease. CRISPR and the Cas gene, particularly Cas9, are used in personalized medicine, enabling precise modifications to an individual’s genetic material and holding promise for breakthroughs in developing tailored therapies for genetic disorders, cancer, and various medical conditions. For instance, in January 2023, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the rising demand for personalized therapy will drive the growth of the CRISPR and Cas gene markets.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13632&type=smp

The crispr and cas gene market covered in this report is segmented –

1) By Product Type: Kits And Enzymes, Libraries, Design Tool, Antibodies, Other Products Types

2) By Service Type: Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis

3) By Application: Clinical, Financial, Operational And Administrative

4) By End Use: Biotechnology And Pharmaceutical Companies, Academics And Government Research Institutes, Contract Research Organizations (CROs)

Major companies operating in the CRISPR and Cas gene markets are developing innovative products such as CRISPR-based cell-based gene therapy to enhance product offerings and gain a competitive advantage. CRISPR-based cell-based gene therapy involves using the CRISPR gene-editing technology to modify or correct genetic material within cells, offering a targeted and potentially revolutionary approach to treating genetic disorders, diseases, and other medical conditions at the cellular level. For instance, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical company, received approval for CASGEVY (exagamglogene autotemcel [exa-cel]) from the U.S. Food and Drug Administration (FDA). CASGEVY is a CRISPR/Cas9 genome-edited gene therapy for the management of sickle cell disease (SCD) in individuals aged 12 and above who have recurrent vaso-occlusive crises. CASGEVY is a first-of-its-kind medication that has the potential to be a one-time transformational therapy for qualified sickle cell patients. CASGEVY administration necessitates specific training in stem cell transplantation, hence, Vertex is collaborating with experienced institutions to create a network of independently owned, approved treatment centers (ATCs) across the United States to provide CASGEVY to patients

The crispr and cas gene market report table of contents includes:

1. Executive Summary

2. CRISPR And Cas Gene Market Characteristics

3. CRISPR And Cas Gene Market Trends And Strategies

4. CRISPR And Cas Gene Market – Macro Economic Scenario

5. Global CRISPR And Cas Gene Market Size and Growth

26. South America CRISPR And Cas Gene Market

27. Brazil CRISPR And Cas Gene Market

28. Middle East CRISPR And Cas Gene Market

29. Africa CRISPR And Cas Gene Market

30. CRISPR And Cas Gene Market Competitive Landscape And Company Profiles

Top Major Players: